In particular, patients with mutant IDH1/2 GBM have a better outcome compared to those with wild-type IDH tumor (14 months with wild-type IDH vs 42 months with mutant IDH) (Fig. 2) [36]. This evidence concerns the gene IDH1 and glioblastoma.